Cutaneous toxicities of antiretroviral therapy for HIV Part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors
ABSTRACT Antiretroviral medications for the treatment of HIV are common drugs with diverse and frequent skin manifestations. Multiple new cutaneous effects have been recognized in the past decade. Dermatologists play an important role in accurately diagnosing and managing the cutaneous toxicities of these medications, thereby ensuring that a patient has as many therapeutic options as possible for life-long viral suppression. Part I of this two-part series on the cutaneous adverse effects of antiretroviral medications will discuss HIV-associated lipodystrophy syndrome, which can be seen as a result of many antiretroviral medications for HIV, and the specific cutaneous effects of the nucleoside reverse transcriptase inhibitors and protease inhibitors.
- SourceAvailable from: onlinelibrary.wiley.comAmerican Journal of Hematology 01/2012; 87(1):131. DOI:10.1002/ajh.22204 · 3.48 Impact Factor
- Piel 08/2012; 27(7):361-364. DOI:10.1016/j.piel.2012.01.007
- [Show abstract] [Hide abstract]
ABSTRACT: Palmoplantar erythrodysesthesia is an uncommon localised cutaneous reaction to certain chemotherapeutic agents and characterized by painful palmoplantar erythema and dysesthesia. To the best of our knowledge, we report the first case of plantar erythrodysesthesia in a 40-year-old male patient receiving an antiretroviral combination therapy for HIV.Case Reports in Medicine 06/2013; 2013:757496. DOI:10.1155/2013/757496